Inozyme Pharma, Inc. (INZY) Tops Q3 EPS by 5c

Inozyme Pharma, Inc. (NASDAQ: INZY) reported Q3 EPS of ($0.39), $0.05 better than the analyst estimate of ($0.44).

For earnings history and earnings-related data on Inozyme Pharma, Inc. (INZY) click here.

You May Also Be Interested In

• Robinhood Ventures Fund II opens at $22.50, IPO at $25
• Sandisk targets mid-to-high teens revenue growth through FY2030
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02